From strategy to scale: a framework for operationalizing and evaluating dementia care coordination in Canada
Allison Alvares, Raymond Dominguez, Saskia Sivananthan, Alexandra Whate, Larry Chambers | ABSTRACT – In 2019, Canada
The impact of innovative medicines on healthcare costs in Canada 1990 to 2024: $20 billion cumulative annual variation in spending on patent drugs saved $70 billion in overall public healthcare expenditure.
Brett J Skinner, PhD | Founder and CEO, CHPI; Editor-in-Chief, CHPJ | ABSTRACT – Few
Reimbursement recommendations for new medicines in Canada: current trends in an uncertain era
Nigel S. B. Rawson, PhD | Affiliated scholar/Senior fellow, Canadian Health Policy Institute, Macdonald-Laurier Institute,
POST CONFERENCE REPORT
The Innovation Legacy: Building a Healthier Future CONFERENCE REPORT Canadian Health Policy Institute (CHPI) and 3Sixty Public
Canada’s medication spending has been relatively low; may need to be reconsidered because of US “most-favored nation” pharma pricing policy
Gerry Jeffcott | 3Sixty Public Affairs | ABSTRACT – Background: Public discourse often frames innovative
Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Brett J Skinner, PhD | CEO, CHPI; Editor, CHPJ | ABSTRACT – The global cost
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | ABSTRACT – Seasonal influenza